{"classes":[{"categories":[{"measurements":[{"groupId":"OG003","lowerLimit":"3198.9","upperLimit":"18374.8","value":"4041.3"},{"groupId":"OG004","lowerLimit":"0","upperLimit":"46542.7","value":"23271.4"},{"groupId":"OG005","lowerLimit":"0","upperLimit":"39676.1","value":"4904.71"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"10"},{"groupId":"OG006","value":"0"}],"units":"Participants"},{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"16"},{"groupId":"OG006","value":"0"}],"units":"Blood samples"}],"title":"Day 1"},{"categories":[{"measurements":[{"groupId":"OG003","lowerLimit":"19237.6","upperLimit":"44659.6","value":"30161.9"},{"groupId":"OG004","lowerLimit":"39500.5","upperLimit":"46542.7","value":"43021.6"},{"groupId":"OG005","lowerLimit":"0","upperLimit":"52133.4","value":"22317.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"10"},{"groupId":"OG006","value":"0"}],"units":"Participants"},{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"15"},{"groupId":"OG006","value":"0"}],"units":"Blood samples"}],"title":"Day 29"},{"categories":[{"measurements":[{"groupId":"OG003","lowerLimit":"33714.8","upperLimit":"49317.2","value":"45003.9"},{"groupId":"OG004","upperLimit":"32364.0","value":"32364.0"},{"groupId":"OG005","lowerLimit":"0","upperLimit":"33450.0","value":"16527.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"10"},{"groupId":"OG006","value":"0"}],"units":"Participants"},{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"13"},{"groupId":"OG006","value":"0"}],"units":"Blood samples"}],"title":"Day 57"},{"categories":[{"measurements":[{"groupId":"OG003","lowerLimit":"10902.5","upperLimit":"26933.5","value":"18918.0"},{"groupId":"OG004","upperLimit":"10662.5","value":"10662.5"},{"groupId":"OG005","lowerLimit":"1594.0","upperLimit":"38181.6","value":"11842.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"10"},{"groupId":"OG006","value":"0"}],"units":"Participants"},{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"10"},{"groupId":"OG006","value":"0"}],"units":"Blood samples"}],"title":"Day 180"},{"categories":[{"measurements":[{"comment":"One out of two participants and one sample analyzed here.","groupId":"OG003","lowerLimit":"NA","upperLimit":"22329.9","value":"22329.9"},{"comment":"One sample analyzed here.","groupId":"OG004","lowerLimit":"NA","upperLimit":"2331.7","value":"2331.7"},{"groupId":"OG005","lowerLimit":"1855.4","upperLimit":"114586.3","value":"8555.06"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"10"},{"groupId":"OG006","value":"0"}],"units":"Participants"},{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"9"},{"groupId":"OG006","value":"0"}],"units":"Blood samples"}],"title":"Day 360"}],"denomUnitsSelected":"Blood samples","denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"10"},{"groupId":"OG006","value":"0"}],"units":"Participants"},{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"63"},{"groupId":"OG006","value":"0"}],"units":"Blood samples"}],"description":"Immunogenicity of mRNA 1273 administered in 2 doses was assessed by titer or level of specific binding antibody (bAb), in participants with hematologic malignancy with or without ongoing immune suppression and patients with solid tumor receiving programmed death-1 (PD-1)/programmed death-ligand 1 inhibitor (PD-L1) inhibitors. Titer or level of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific binding antibody (bAb) measured by enzyme-linked immunosorbent assay (ELISA) on Day 1, Day 29, Day 57, Day 180, and Day 360. Participants received one or two vaccine boosters. Analysis of timepoints after booster 1 and booster 2 are reported collectively.","dispersionType":"Full Range","groups":[{"description":"100 mcg (0.5 mL) messenger ribonucleic acid (mRNA)-1273 injection on day (D)1.","id":"OG000","title":"Chronic Lymphocytic Leukemia (CLL) Not on Active Therapy - Booster Phase"},{"description":"100 mcg (0.5 mL) messenger ribonucleic acid (mRNA)-1273 injection on day (D)1.","id":"OG001","title":"Chronic Lymphocytic Leukemia(CLL) Receiving Bruton´s Tyrosine Kinase(BTK) Interruption-Booster Phase"},{"description":"100 mcg (0.5 mL) messenger ribonucleic acid (mRNA)-1273 injection on day (D)1.","id":"OG002","title":"Chimeric Antigen Receptor (CAR) T Cell Therapy - Booster Phase"},{"description":"100 mcg (0.5 mL) messenger ribonucleic acid (mRNA)-1273 injection on day (D)1.","id":"OG003","title":"Solid Tumor on Programmed Cell Death protein1/Programmed Cell Death Ligand 1 Inhibitor-Booster Phase"},{"description":"100 mcg (0.5 mL) messenger ribonucleic acid (mRNA)-1273 injection on day (D)1.","id":"OG004","title":"Post Allogeneic Transplant - Booster Phase"},{"description":"100 mcg (0.5 mL) messenger ribonucleic acid (mRNA)-1273 injection, intramuscular (IM) on day 1.","id":"OG005","title":"Other Hematologic Malignancy - Booster Phase"},{"description":"100 mcg (0.5 mL) messenger ribonucleic acid (mRNA)-1273 injection on day (D)1.","id":"OG006","title":"Other Adult Solid Tumor - Booster Phase"}],"paramType":"MEDIAN","populationDescription":"No participants were enrolled in Groups CLL, CLL/BTK, CAR-T Cell and Other Adult Solid Tumor Booster Phase. Regarding Other Hematologic Malignancy Booster Phase Group 1 participant crossed over from hematologic low immunosuppression-initial phase; 3 participants crossed over from hematologic intermediate immunosuppression-initial phase; 3 participants crossed over from hematologic high immunosuppression-initial phase; \\& 3 participants were initially enrolled (did not cross over) into this group.","reportingStatus":"POSTED","timeFrame":"Day 1, Day 29, Day 57, Day 180, and Day 360","title":"Immunogenicity of Messenger Ribonucleic Acid (mRNA) -1273 Levels Administered in 2 Doses in the Booster Phase","type":"SECONDARY","typeUnitsAnalyzed":"Blood samples","unitOfMeasure":"AU/mL"}